FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 29 filers reported holding FUSION PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,104,112 | -44.4% | 3,116,966 | 0.0% | 0.01% | -45.5% |
| Q2 2023 | $14,587,401 | +24.1% | 3,116,966 | 0.0% | 0.02% | +15.8% |
| Q1 2023 | $11,750,962 | +19.7% | 3,116,966 | 0.0% | 0.02% | +11.8% |
| Q4 2022 | $9,818,443 | +4.7% | 3,116,966 | 0.0% | 0.02% | +6.2% |
| Q3 2022 | $9,382,000 | +20.9% | 3,116,966 | 0.0% | 0.02% | +23.1% |
| Q2 2022 | $7,761,000 | -68.0% | 3,116,966 | 0.0% | 0.01% | -59.4% |
| Q1 2022 | $24,219,000 | +86.3% | 3,116,966 | 0.0% | 0.03% | +128.6% |
| Q4 2021 | $12,998,000 | -47.3% | 3,116,966 | 0.0% | 0.01% | -50.0% |
| Q3 2021 | $24,686,000 | -2.0% | 3,116,966 | 0.0% | 0.03% | -6.7% |
| Q2 2021 | $25,185,000 | -24.6% | 3,116,966 | 0.0% | 0.03% | -31.8% |
| Q1 2021 | $33,414,000 | -8.8% | 3,116,966 | 0.0% | 0.04% | -20.0% |
| Q4 2020 | $36,624,000 | -2.2% | 3,116,966 | 0.0% | 0.06% | -22.5% |
| Q3 2020 | $37,466,000 | -31.2% | 3,116,966 | 0.0% | 0.07% | -38.8% |
| Q2 2020 | $54,453,000 | – | 3,116,966 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,543,342 | 3.52% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,664,303 | 2.68% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $4,058,553 | 1.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,354,258 | $3,521,071 | 0.64% |
| Avidity Partners Management LP | 5,781,850 | $15,032,810 | 0.60% |
| Eagle Health Investments LP | 579,769 | $1,507,399 | 0.33% |
| Perceptive Advisors | 2,751,395 | $7,153,627 | 0.24% |
| Ghost Tree Capital, LLC | 243,287 | $632,546 | 0.21% |
| Sio Capital Management, LLC | 246,036 | $639,694 | 0.20% |
| Artal Group S.A. | 1,725,000 | $4,485 | 0.19% |